The Food and Drug Administration (FDA) is planning to roll out artificial intelligence across the agency following a successful pilot program.
FDA Commissioner Dr. Marty Makary has directed all FDA centers to immediately start using artificial intelligence (AI) and fully integrate it by the end of June, the FDA said in a May 8 statement.
By June 30, all centers will use what the agency described as a “common, secure generative AI system integrated with FDA’s internal data platforms.”
“I was blown away by the success of our first AI-assisted scientific review pilot,” Makary said in a statement. “We need to value our scientists’ time and reduce the amount of non-productive busywork that has historically consumed much of the review process. The agency-wide deployment of these capabilities holds tremendous promise in accelerating the review time for new therapies.”…